HRP20211913T1 - Spoj pirimidina - Google Patents
Spoj pirimidina Download PDFInfo
- Publication number
- HRP20211913T1 HRP20211913T1 HRP20211913TT HRP20211913T HRP20211913T1 HR P20211913 T1 HRP20211913 T1 HR P20211913T1 HR P20211913T T HRP20211913T T HR P20211913TT HR P20211913 T HRP20211913 T HR P20211913T HR P20211913 T1 HRP20211913 T1 HR P20211913T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- alkyl
- halogen
- salt
- image
- Prior art date
Links
- -1 Pyrimidine compound Chemical class 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical group 0.000 claims 7
- 206010010904 Convulsion Diseases 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 1
- 208000002091 Febrile Seizures Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 1
- 229910052805 deuterium Inorganic materials 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000028329 epileptic seizure Diseases 0.000 claims 1
- 206010016284 febrile convulsion Diseases 0.000 claims 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 208000005809 status epilepticus Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (8)
1. Spoj predstavljen formulom [I]:
[image]
pri čemu
prsten A je fenil, naftil ili piridil;
R1 je C1-6 alkil;
R2 je -O-C1-6 alkil;
R3 je halogen, C2-6 alkinil, C1-6 alkil izborno supstituiran s halogenom, -O-C1-6 alkil izborno supstituiran s deuterijem ili halogenom, -S-C1-6 alkil izborno supstituiran s halogenom, fenilom, pentafluorotio, -CN , -O-
benzil ili -Si-mono-, di- ili tri-C1-6 alkil pri čemu di ili tri mogu biti isti ili različit alkil;
L je veza, C1-6 alkilen, -O- ili -S-;
svaki od m i n je 0 ili 1;
q je 0, 1 ili 2, i kada q je 2, svaki R3 neovisno predstavlja isti ili različit supstituent; i
[image]
predstavlja jednostruku ili dvostruku vezu,
ili njegova sol.
2. Spoj ili njegova sol prema zahtjevu 1, naznačen time što
prsten A je fenil,
L je -O-, i
n je 0.
3. Spoj ili njegova sol prema zahtjevu 1 ili 2, naznačen time što m je 0.
4. Spoj ili njegova sol prema bilo kojem od zahtjeva 1 do 3, naznačen time što R3 je halogen, C2-6 alkinil, C1-6 alkil ili -S-C1-6 alkil izborno supstituiran s halogenom.
5. Spoj ili njegova sol prema bilo kojem od zahtjeva 1 do 4, naznačen time što
[image]
je fenil, monohalofenil, dihalofenil, mono-C2-6 alkinilfenil ili mono-C1-6 alkilfenil ili fenil supstituiran s jednim halogenom i jednom C1-6 alkilnom skupinom.
6. Spoj ili njegova sol prema zahtjevu 1, koji se bira iz skupine koju čine sljedeći spojevi:
[image]
[image]
[image]
ili njegova sol.
7. Farmaceutski pripravak koji sadrži spoj ili njegovu sol prema bilo kojem od zahtjeva 1 do 6 kao aktivni sastojak i farmaceutski prihvatljiv nosač ili ekscipijens.
8. Spoj ili njegova sol prema bilo kojem od zahtjeva 1 do 6 za uporabu u liječenju, prevenciji i/ili dijagnostici napadaja u bolesti koja uključuje epileptički napadaj ili konvulzivni napadaj (uključujući napadaj otporan na više lijekova, refraktorni napadaj, akutni simptomatski napadaj, febrilni napadaj i epileptični status).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2017/020322 WO2018220762A1 (ja) | 2017-05-31 | 2017-05-31 | ピリミジン化合物 |
| PCT/JP2018/020997 WO2018221667A1 (en) | 2017-05-31 | 2018-05-31 | Pyrimidine compound |
| EP18732930.5A EP3630729B1 (en) | 2017-05-31 | 2018-05-31 | Pyrimidine compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211913T1 true HRP20211913T1 (hr) | 2022-03-04 |
Family
ID=62685028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211913TT HRP20211913T1 (hr) | 2017-05-31 | 2018-05-31 | Spoj pirimidina |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10800758B2 (hr) |
| EP (1) | EP3630729B1 (hr) |
| JP (1) | JP6739653B2 (hr) |
| KR (1) | KR20200011962A (hr) |
| CN (1) | CN110603248B (hr) |
| AU (1) | AU2018277949B2 (hr) |
| BR (1) | BR112019023988A2 (hr) |
| CA (1) | CA3064176A1 (hr) |
| CY (1) | CY1125073T1 (hr) |
| DK (1) | DK3630729T3 (hr) |
| EA (1) | EA038907B1 (hr) |
| ES (1) | ES2901452T3 (hr) |
| HR (1) | HRP20211913T1 (hr) |
| HU (1) | HUE056942T2 (hr) |
| IL (1) | IL270579B2 (hr) |
| LT (1) | LT3630729T (hr) |
| MX (1) | MX2019014384A (hr) |
| PH (1) | PH12019502639A1 (hr) |
| PL (1) | PL3630729T3 (hr) |
| PT (1) | PT3630729T (hr) |
| SA (1) | SA519410563B1 (hr) |
| SI (1) | SI3630729T1 (hr) |
| TW (2) | TW202346283A (hr) |
| WO (2) | WO2018220762A1 (hr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6870064B2 (ja) * | 2018-11-30 | 2021-05-12 | 大塚製薬株式会社 | ピリミジン化合物の医薬用途 |
| EP3887358A1 (en) * | 2018-11-30 | 2021-10-06 | Otsuka Pharmaceutical Co., Ltd. | Heterocyclic compounds for the treatment of epilepsy |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004009559A2 (en) * | 2002-07-18 | 2004-01-29 | Queen's University At Kingston | Dihydrouracil compounds as anti-ictogenic or anti-epileptogenic agents |
| EA019970B8 (ru) | 2009-12-11 | 2014-11-28 | Отифони Терапеутикс Лимитед | Производные имидазолидиндиона |
| MX2012008346A (es) * | 2010-01-25 | 2012-11-12 | Chdi Foundation Inc | Determinados inhibidores de cinurenina-3-monooxigenasa, composiciones farmceuticas y metodos de uso de los mismos. |
| BR112013013914B1 (pt) * | 2010-12-06 | 2021-10-26 | Autifony Therapeutics Limited | Compostos derivados de hidantoína úteis como inibidores de kv3, usos dos referidos compostos e composição farmacêutica compreendendo os mesmos |
| WO2012168710A1 (en) * | 2011-06-07 | 2012-12-13 | Autifony Therapeutics Limited | Hydantoin derivates as kv3 inhibitors |
| WO2013016488A1 (en) * | 2011-07-28 | 2013-01-31 | Celia Dominguez | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| KR20140098850A (ko) | 2011-12-06 | 2014-08-08 | 오티포니 세라피틱스 리미티드 | Kv3 억제제로서 유용한 하이단토인 유도체 |
| GB201521751D0 (en) * | 2015-12-10 | 2016-01-27 | Autifony Therapeutics Ltd | Novel uses |
-
2017
- 2017-05-31 WO PCT/JP2017/020322 patent/WO2018220762A1/ja active Application Filing
-
2018
- 2018-05-30 TW TW112129778A patent/TW202346283A/zh unknown
- 2018-05-30 TW TW107118471A patent/TWI808974B/zh active
- 2018-05-31 US US16/471,998 patent/US10800758B2/en active Active
- 2018-05-31 MX MX2019014384A patent/MX2019014384A/es unknown
- 2018-05-31 SI SI201830499T patent/SI3630729T1/sl unknown
- 2018-05-31 JP JP2019535398A patent/JP6739653B2/ja active Active
- 2018-05-31 EP EP18732930.5A patent/EP3630729B1/en active Active
- 2018-05-31 BR BR112019023988-0A patent/BR112019023988A2/pt unknown
- 2018-05-31 HR HRP20211913TT patent/HRP20211913T1/hr unknown
- 2018-05-31 CN CN201880030366.XA patent/CN110603248B/zh active Active
- 2018-05-31 AU AU2018277949A patent/AU2018277949B2/en active Active
- 2018-05-31 PL PL18732930T patent/PL3630729T3/pl unknown
- 2018-05-31 PT PT187329305T patent/PT3630729T/pt unknown
- 2018-05-31 EA EA201992831A patent/EA038907B1/ru unknown
- 2018-05-31 HU HUE18732930A patent/HUE056942T2/hu unknown
- 2018-05-31 CA CA3064176A patent/CA3064176A1/en active Pending
- 2018-05-31 DK DK18732930.5T patent/DK3630729T3/da active
- 2018-05-31 ES ES18732930T patent/ES2901452T3/es active Active
- 2018-05-31 WO PCT/JP2018/020997 patent/WO2018221667A1/en active Application Filing
- 2018-05-31 KR KR1020197037748A patent/KR20200011962A/ko not_active Application Discontinuation
- 2018-05-31 LT LTEPPCT/JP2018/020997T patent/LT3630729T/lt unknown
-
2019
- 2019-11-12 IL IL270579A patent/IL270579B2/en unknown
- 2019-11-14 SA SA519410563A patent/SA519410563B1/ar unknown
- 2019-11-22 PH PH12019502639A patent/PH12019502639A1/en unknown
-
2020
- 2020-09-02 US US17/010,182 patent/US20200399245A1/en not_active Abandoned
-
2021
- 2021-12-13 CY CY20211101091T patent/CY1125073T1/el unknown
-
2022
- 2022-12-30 US US18/091,790 patent/US20230138411A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200538T1 (hr) | Derivati pirimidina za liječenje virusnih infekcija | |
| HRP20200840T1 (hr) | Pripravci i postupci za liječenje poremećaja cns-a | |
| HRP20200648T1 (hr) | Derivati sulfamoilpirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b | |
| HRP20150427T1 (hr) | Ne-nukleozidni inhibitori reverzne transkriptaze | |
| HRP20171957T1 (hr) | Derivati 2-(2,4,5-supstituiranog-anilino) pirimidina kao modulatori egfr koji su korisni za liječenje raka | |
| HRP20180483T1 (hr) | Spoj kinolona | |
| HRP20161125T1 (hr) | Makrociklički purini za liječenje virusnih infekcija | |
| HRP20191901T1 (hr) | Ciklizirani derivati sulfamoilarilamida i njihova uporaba kao lijekova za liječenje hepatitisa b | |
| HRP20130976T1 (hr) | Karbonilaminopirolopirazoli, potentni inhibitori kinaza | |
| WO2017205536A3 (en) | Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer | |
| HRP20170654T1 (hr) | Makrociklički deaza-purinoni za liječenje virusnih infekcija | |
| HRP20160852T1 (hr) | Biciklični heterociklični spojevi kao inhibitori protein tirozin kinaze | |
| HRP20220899T1 (hr) | Spojevi policikličkog karbamoilpiridona i njihova farmaceutska uporaba | |
| WO2015132799A3 (en) | Heterocyclic compounds | |
| SI3024819T1 (en) | Glyoxamide-substituted pyrrolamide derivatives and their use as medicines for the treatment of hepatitis B | |
| PE20170127A1 (es) | Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas | |
| HRP20211278T1 (hr) | Supstituirani derivati indolina kao inhibitori replikacije denga virusa | |
| JP2013527242A5 (hr) | ||
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| JP2017537949A5 (hr) | ||
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| TN2019000204A1 (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| NZ592238A (en) | Pharmaceutical compositions comprising 4-isopropyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine derivatives | |
| AR045389A1 (es) | Inhibidores del c-kit con estructura de pirazolil-amidil-benzoimidazolilo n-sustituido | |
| RU2017145922A (ru) | МОДУЛЯТОРЫ ROR ГАММА(RORy) |